AstraZeneca: FASENRA Met the Primary Endpoint in the MANDARA Phase III Trial in Eosinophilic Granulomatosis With Polyangiitis
September 12, 2023
September 12, 2023
WILMINGTON, Delaware, Sept. 12 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
Positive high-level results from the MANDARA Phase III trial showed AstraZeneca's FASENRA (benralizumab) met the primary endpoint of the trial and demonstrated non-inferior rates of remission compared to mepolizumab in patients with eosinophilic granulomatosis with polyangiitis (EGPA) who were receiving oral corticosteroids (OCS) with or without stable immunosuppre . . .
Positive high-level results from the MANDARA Phase III trial showed AstraZeneca's FASENRA (benralizumab) met the primary endpoint of the trial and demonstrated non-inferior rates of remission compared to mepolizumab in patients with eosinophilic granulomatosis with polyangiitis (EGPA) who were receiving oral corticosteroids (OCS) with or without stable immunosuppre . . .